AVI BioPharma to Present Novel Antisense Approach at Leading Interventional Cardiology Conference.Business Editors & Health/Medical Writers PORTLAND, Ore.--(BW HealthWire)--May 17, 2002 Resten-NG(TM) Shows Superior Properties for Preventing Coronary Occlusion Following Angiography angiography or arteriography X-ray examination of arteries and veins with a contrast medium to differentiate them from surrounding organs. The contrast medium is introduced through a catheter to show the blood vessels and the structures they supply, including and Stent Placement AVI BioPharma, Inc. (Nasdaq:AVII) (Nasdaq:AVIIW) (Nasdaq:AVIIZ), today announced that Denis Denis, king of Portugal: see Diniz. R. Burger, Ph.D., AVI's chief executive officer, and AVI (Audio Video Interleaved) A Windows multimedia video format from Microsoft. It interleaves standard waveform audio and digital video frames (bitmaps) to provide reduced animation at 15 fps at 160x120x8 resolution. Audio is 11,025Hz, 8-bit samples. scientist, Derek Knapp will present data showing the efficacy of AVI's third-generation antisense antisense, DNA or RNA manipulated in a laboratory so that its components (nucleotides) form a complementary copy of normal, or "sense," messenger RNA (mRNA; see nucleic acid). drug, Resten-NG(TM), in preventing coronary restenosis, at the 25th annual conference of The Society for Cardiac Angiography and Interventions in Seattle. On May 17 from 8:30-10:30 a.m. Mr. Knapp will present: "Local delivery of a third generation c-myc antisense: Concept, experimental results and future directions." Results of the study demonstrate that Resten-NG is highly effective in the inhibition of coronary artery smooth muscle cell growth and preservation of vascular endothelial cells, thus promoting the repair of vascular injury caused by angioplasty procedures. These favorable properties were not observed for rapamycin or paclitaxel paclitaxel /pac·li·tax·el/ (pak?li-tak´sel) an antineoplastic that promotes and stabilizes polymerization of microtubules, isolated from the Pacific yew tree (Taxus brevifolia); , which also are being evaluated by interventional cardiologists. At a concurrent session on May 17 from 3:30-5 p.m. Dr. Burger will discuss the application of AVI's antisense technology for coated stents. "AVI is very pleased to be sharing the stage with leading members of the cardiology community," Dr. Burger said. "Coronary artery disease coronary artery disease, condition that results when the coronary arteries are narrowed or occluded, most commonly by atherosclerotic deposits of fibrous and fatty tissue. is a key clinical development area for AVI as evidenced by its late-stage clinical program for coated stents with Medtronic, Inc. In addition, late last month we announced the initiation of a clinical development program with Thomas Jefferson University It began as Jefferson Medical College in 1824. On July 1, 1969 the institution officially became Thomas Jefferson University. The university is made up of three colleges:
About Resten-NG: Resten-NG is a NEUGENE(R) compound for treating cardiovascular restenosis, or the renarrowing of an artery following balloon angioplasty. Resten-NG targets a transcription factor, and upon entering arterial cells, it blocks the underlying cause of the disease: smooth muscle cell activation and proliferation. AVI has demonstrated in preclinical studies that Resten-NG significantly reduced coronary restenosis. A global license has been granted to Medtronic for AVI's antisense compounds deployed on stents or other devices for treating restenosis. AVI is currently in a Phase II trial with this product. About AVI BioPharma AVI BioPharma develops therapeutic products for the treatment of life-threatening diseases using two technology platforms: NEUGENE antisense drugs and cancer immunotherapy. Its lead cancer agent, AVICINE(R), a therapeutic cancer vaccine, has completed three Phase II trials in colorectal and pancreatic cancer and is initiating a Phase III pivotal trial in pancreatic cancer, with a supporting study in colorectal cancer. The first application of its NEUGENE compounds, Resten-NG, is designed to treat cancer, cardiovascular restenosis and other cell proliferation disorders by inhibiting the production of a cellular transcription factor, the oncogene oncogene Gene that can cause cancer. It is a sequence of DNA that has been altered or mutated from its original form, the proto-oncogene (see mutation). Proto-oncogenes promote the specialization and division of normal cells. c-myc. It is currently in Phase II trials for restenosis and in Phase I/II trials for cancer and polycystic kidney disease Polycystic Kidney Disease Definition Polycystic kidney disease (PKD) is one of the most common of all life-threatening human genetic disorders. . AVI has recently completed a Phase I NEUGENE antisense study that successfully down-regulated the liver enzyme Cytochrome P450 and modified drug metabolism. More information about AVI is available on the Company's Web site at http://www.avibio.com/. "Safe Harbor" Statement under the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995: The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the Companies' Securities and Exchange Commission filings. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion